Danish pharmaceutical company Genmab announced that Johnson & Johnson's global sales of the blood cancer drug Darzalex amounted to just under $14.4 billion in 2025, according to a press release.
Sales were divided between $8,266 million in the United States and $6,085 million in the rest of the world.
Genmab receives royalties on the global sales of Darzalex from Janssen Biotech, which is owned by the American company Johnson & Johnson. J&J released its quarterly report for the fourth quarter on Wednesday.
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (80.6%);
- income from research and development (9.3%);
- other (10.1%): primarily income from partnership agreement.
At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
